{"id":"W4324136935","doi":"10.1200/jco.2023.41.6_suppl.lba441","title":"Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Metastatic Urothelial Carcinoma; Atezolizumab; Interim analysis; Gemcitabine; Oncology; Population; Phases of clinical research; Urology; Clinical trial; Chemotherapy; Cancer; Pembrolizumab; Bladder cancer; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006967995,0.001323576,0.002321135,0.0005824441,0.0002431909,0.001013053,0.001027762,0.001315661,0.003107884],"category_scores_gemma":[0.002323242,0.0003786298,0.003863013,0.0006089777,0.000561411,0.0007023832,0.0008347422,0.002921339,0.000566102],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007999124,"about_ca_system_score_gemma":0.001027736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005400082,"about_ca_topic_score_gemma":0.00166698,"domain_scores_codex":[0.9984729,0.001007733,0.00007784542,0.0001689677,0.0001138872,0.000158617],"domain_scores_gemma":[0.9981142,0.0005508176,0.0003885563,0.0002231712,0.0001034611,0.0006196909],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9185256,0.004129724,0.01209874,0.001094677,0.006295873,0.0001199287,0.0001271935,0.002868876,0.008984548,0.0001908078,0.004243334,0.04132064],"study_design_scores_gemma":[0.433295,0.4361634,0.100833,0.0002495931,0.01385224,0.0004284116,0.0001252288,0.002957088,0.003936657,0.0008842673,0.007199379,0.00007575801],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761627,0.007317862,0.001431449,0.0006838387,0.0001496552,0.002022693,0.009100671,0.0001169002,0.003014307],"genre_scores_gemma":[0.9771842,0.001792113,0.001781967,0.001057007,0.0001615996,0.001901304,0.01444793,0.00007371799,0.001600144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006967995,"threshold_uncertainty_score":0.03685069,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1718692902279652,"score_gpt":0.4882059433640002,"score_spread":0.316336653136035,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}